Patient Portal

John F. DiPersio, MD, PhD

Virginia E. and Samuel J Golman Endowed Professorship of Medicine, Pathology & Immunology
Professor, Pediatrics
Professor, Pathology
Chief, Division of Oncology
Deputy Director, Siteman Cancer Center

Specialty Areas

Bone Marrow Transplant
Hematology
Leukemia
Hematologic Malignancies
Gene Therapy

Board Certifications

Hematology
Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Hematology, oncology, bone marrow transplantation, hematopoietic stem cell transplantation, molecular biology, cellular biology, leukemia, MDS, aplastic anemia

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-454-8304
Fax: 314-454-7551

Education

Education

Fellowship: Hematology & Oncology, UCLA School of Medicine, Los Angeles, CA 1987
Chief Resident: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1984
Residency: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1983
Ph.D.: Microbiology, University of Rochester School of Medicine, Rochester, NY 1980
Medical Degree: University Of Rochester School of Medicine, Rochester, NY 1980
B.A.: Biology, Williams College 1973

Publication & Research

Publication & Research

The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-Versus-Host Disparity Is Associated with Increased Acute Graft-Versus-Host Disease in Haploidentical Transplantation with Post-Transplant Cyclophosphamide.
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R
Biol Blood Marrow Transplant. 2019 Sep 26; pii: S1083-8791(19)30635-4. doi: 10.1016/j.bbmt.2019.09.024.

PMID:
    31563575
    [PubMed - as supplied by publisher]
Related citations


GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.
Crees ZD, Stockerl-Goldstein K, Vainstein A, Chen H, DiPersio JF
Future Oncol. 2019 Sep 9; doi: 10.2217/fon-2019-0380.

PMID:
    31495201
    [PubMed - as supplied by publisher]
Related citations


A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev A, Beaven AW, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM
Clin Cancer Res. 2019 Sep 3; pii: clincanres.0438.2019. doi: 10.1158/1078-0432.CCR-19-0438.

PMID:
    31481504
    [PubMed - as supplied by publisher]
Related citations


The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.
Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I
Am J Transplant. 2019 Aug 25; doi: 10.1111/ajt.15579.

PMID:
    31446673
    [PubMed - as supplied by publisher]
Related citations


Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y
Biol Blood Marrow Transplant. 2019 Aug 22; pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015.

PMID:
    31446199
    [PubMed - as supplied by publisher]
Related citations


A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, DiPersio JF
Clin Lymphoma Myeloma Leuk. 2019 May 2; pii: S2152-2650(19)30019-9. doi: 10.1016/j.clml.2019.04.017.

PMID:
    31358485
    [PubMed - as supplied by publisher]
Related citations


Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK
Bone Marrow Transplant. 2019 May 15; doi: 10.1038/s41409-019-0451-2.

PMID:
    31092900
    [PubMed - as supplied by publisher]
Related citations


Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF
J Clin Invest. 2019 May 14; 129(7)2745-2759. doi: 10.1172/JCI124738.

PMID:
    31085833
    [PubMed - in process]
Related citations


Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia.
Ghobadi A, Miller CA, Li T, O'Laughlin M, Lee YS, Ali M, Westervelt P, DiPersio JF, Wartman L
Haematologica. 2019 Aug; 104(8)e373-e375. doi: 10.3324/haematol.2019.217794.

PMID:
    30923101
    [PubMed - in process]
Related citations


Immune Escape of AML Cells after Transplantation. Reply.
Christopher M, DiPersio JF, Ley TJ
N Engl J Med. 2019 Mar 28; 380(13)1290. doi: 10.1056/NEJMc1900424.

PMID:
    30917273
    [PubMed - indexed for MEDLINE]
Related citations


Dynamic host immune response in virus-associated cancers.
Cao S, Wylie KM, Wyczalkowski MA, Karpova A, Ley J, Sun S, Mashl RJ, Liang WW, Wang X, Johnson K, DiPersio JF, Gay H, Ratner L, Chen F, Adkins DR, Ding L
Commun Biol. 2019; 2109. doi: 10.1038/s42003-019-0352-3.

PMID:
    30911684
    [PubMed]
Related citations


Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM
Blood Adv. 2019 Mar 26; 3(6)875-883. doi: 10.1182/bloodadvances.2018027599.

PMID:
    30890544
    [PubMed - in process]
Related citations


Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia.
Abboud R, Han SY, Duncavage EJ, Cashen AF, Shirai CL, Welch JS, DiPersio JF, Abboud CN
Haematologica. 2019 Apr; 104(4)e170-e173. doi: 10.3324/haematol.2018.209478.

PMID:
    30733274
    [PubMed - in process]
Related citations


ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS
Biol Blood Marrow Transplant. 2019 Apr; 25(4)625-638. doi: 10.1016/j.bbmt.2018.12.758.

PMID:
    30592986
    [PubMed - in process]
Related citations


Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK
Biol Blood Marrow Transplant. 2019 Mar; 25(3)e76-e85. doi: 10.1016/j.bbmt.2018.12.068.

PMID:
    30576834
    [PubMed - in process]
Related citations


HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R
Blood Adv. 2018 Dec 26; 2(24)3590-3601. doi: 10.1182/bloodadvances.2018025437.

PMID:
    30563883
    [PubMed - indexed for MEDLINE]
Related citations


CiTE antibody for AML.
Rettig MP, DiPersio JF
Blood. 2018 Dec 6; 132(23)2425-2427. doi: 10.1182/blood-2018-10-879668.

PMID:
    30523124
    [PubMed - indexed for MEDLINE]
Related citations


Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD.
Ashami K, DiPersio JF, Choi J
Oncotarget. 2018 Nov 6; 9(87)35721-35722. doi: 10.18632/oncotarget.26291.

PMID:
    30515263
    [PubMed]
Related citations


Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation.
Alahmari B, Cooper M, Ziga E, Ritchey J, DiPersio JF, Choi J
PLoS One. 2018; 13(11)e0207609. doi: 10.1371/journal.pone.0207609.

PMID:
    30452487
    [PubMed - indexed for MEDLINE]
Related citations


Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF
N Engl J Med. 2018 Dec 13; 379(24)2330-2341. doi: 10.1056/NEJMoa1808777.

PMID:
    30380364
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2018:

Company Name: Magenta Therapeutics

Royalties:

Equity: Yes

Consulting/Advisory Board: $1 - $9,999

Speaker Fees:

Reporting Date: May 01, 2019


Company Name: WUGEN

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2019